GlassScriptPhysician profile
Randolph E Schumacher
NPI 1912002999
$8,629.17
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $1,255 · 2021: $1,874 · 2022: $2,010 · 2023: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.54 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.05 | 2020-2023 | Qulipta, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $901.87 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $699.23 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $666.71 | 2019-2023 | |
| Pfizer INC. | $583.48 | 2019-2023 | |
| Amgen INC. | $454.49 | 2019-2023 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $285.88 | 2019-2023 | Rexulti |
| Novo Nordisk INC | $244.72 | 2019-2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $199.68 | 2019-2023 | Freestyle Libre 3 |
| Allergan, INC. | $195.91 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $191.11 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $186.32 | 2019-2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $185.56 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $182.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.47 | 2019-2023 | Xifaxan |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Schumacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.